Hematology

Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

Patients with immunoglobulin M-type monoclonal gammopathy did not experience a survival benefit from targeted therapies, a study found.

The MajesTEC-5 trial shows teclistamab's impressive efficacy in achieving MRD-negative status in newly diagnosed transplant-eligible patients, explains Marc S. Raab, MD, PhD.

Findings suggest bispecific CD3xCD20 therapy may offer an option for patients with Richter syndrome who are ineligible for transplant or CAR T-cell Therapy.

Patients with essential thrombocythemia live with a risk of developing serious bleeding complications, a new study explains.

A case series suggests using minimal residual disease to trigger anti-CD20 therapy for chronic lymphocytic leukemia (CLL) can add years to some patients’ lives.

Patients with hematologic malignancies face ongoing survivorship challenges as providers struggle to coordinate care, according to Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd.

Teclistamab shows promising real-world effectiveness and safety in older adults with relapsed/refractory multiple myeloma (R/R MM), matching clinical trial outcomes.

Four autophagy-related variants in CDKN2A and BCL2 may increase susceptibility to chronic lymphocytic leukemia (CLL).

As oncology continues to move more toward precision medicine, tools like EVOFLUx may offer a more personalized roadmap from diagnosis to treatment.

Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.

Positive topline data from the phase 3 BRUIN CLL-313 showed pirtobrutinib's efficacy in the frontline setting.

The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression.

Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.

Outpatient treatment with axi-cel shows promising response rates for relapsed large B-cell lymphoma, enhancing accessibility in community oncology settings.

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

Among patients with hematologic malignancies who were diagnosed with COVID-19, about one-quarter experienced critical illness, and most of those patients died.

Cilta-cel demonstrates superior efficacy and durability in treating high-risk myeloma, balancing effectiveness with safety concerns for patients.

Matias Sanchez, MD, a hematologist-oncologist at University of Illinois Health, discussed the latest advancements in value-based multiple myeloma care, including minimal residual disease strategies and innovative targeted therapies.

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need for therapies that offer a sense of normalcy to individuals with polycythemia vera.

The findings could help clinicians individualize infection-prevention strategies in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Outcomes in accelerated-phase (AP) or blast-phase (BP) myeloproliferative neoplasm (MPN) differ from AML, and AML-based frameworks may not fully capture prognosis in this population.

Patients with severe sickle cell disease experienced significant quality of life improvements after receiving exagamglogene autotemcel gene therapy.

A single-center study comparing patients with chronic lymphocytic leukemia receiving venetoclax as part of a clinical trial and patients receiving it in routine clinical practice showed very high complete response rates in both groups.